Savior Lifetec (4167) reported revenue of NT$136.2 million for Oct 2026, +21.3% year on year and +30.8% from the previous month. Revenue for Jan–Oct 2026 was NT$974.4 million (-2.0% year on year).
Year-on-year revenue growth: 3 months in a row. →
In Oct 2026, it ranked No. 59 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$136.2 million | +21.3% | +30.8% |
| Sep 2026 | NT$104.1 million | +33.7% | -11.2% |
| Aug 2026 | NT$117.2 million | +22.3% | +20.2% |
| Jul 2026 | NT$97.5 million | -10.4% | -4.7% |
| Jun 2026 | NT$102.3 million | -0.2% | +16.2% |
| May 2026 | NT$88 million | -23.0% | -8.1% |
| Apr 2026 | NT$95.7 million | -19.4% | +12.1% |
| Mar 2026 | NT$85.4 million | -9.1% | +32.6% |
| Feb 2026 | NT$64.4 million | -10.9% | -23.2% |
| Jan 2026 | NT$83.9 million | -14.2% | -30.0% |
| Dec 2025 | NT$119.7 million | +106.7% | +36.3% |
| Nov 2025 | NT$87.9 million | -23.8% | -21.7% |
| Oct 2025 | NT$112.3 million | +8.2% | +44.3% |
| Sep 2025 | NT$77.8 million | -39.6% | -18.8% |
| Aug 2025 | NT$95.8 million | -12.1% | -12.0% |
| Jul 2025 | NT$108.8 million | +15.1% | +6.2% |
| Jun 2025 | NT$102.5 million | +13.7% | -10.4% |
| May 2025 | NT$114.3 million | -19.9% | -3.7% |
| Apr 2025 | NT$118.7 million | +2.5% | +26.5% |
| Mar 2025 | NT$93.9 million | +1.6% | +30.0% |
| Feb 2025 | NT$72.2 million | +33.5% | -26.1% |
| Jan 2025 | NT$97.8 million | -13.2% | +68.8% |
| Dec 2024 | NT$57.9 million | -46.1% | -49.7% |
| Nov 2024 | NT$115.3 million | +11.5% | +11.1% |
| Oct 2024 | NT$103.7 million | -3.2% | -19.5% |
Jan–Oct 2026 cumulative: NT$974.4 million (-2.0% YoY)
Other Biotech & Medical companies
Compare with peers: Savior Lifetec vs PEC / Savior Lifetec vs Lotus Pharm / Savior Lifetec vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16